SOUTHWEST ONCOLOGY GROUP

描述(摘自申请者的摘要)：西南肿瘤学 得克萨斯大学健康科学小组癌症研究计划 圣安东尼奥中心是一个成员机构的多学科项目 致力于增加大量患者的研究 西南肿瘤学研究组和来自成员的高质量数据收集 机构及其合作小组外联计划(CGOP)附属机构。 首席调查员和48名来自医学的合作调查员 肿瘤学、血液学、外科肿瘤学、放射肿瘤学和病理学 保持20年不间断地参与该合作社 临床试验计划。这个项目达到了一、二级水平。 在所有参与过去患者应计费用的成员机构中 两年了。该成员已将1,202名患者纳入团体研究 从L/L/92至1996年12月31日(363名患者) 仅限成员机构)。在这些患者中，642人或53%是女性 (217或成员机构应计利润的60%)、185%或15% 是西班牙裔(126%或35%的成员机构应计)，152 或13%是非洲裔美国人(35%或10%的成员 机构应计利润)。该计划已经招募了7个新的CGOP附属公司 共有17个CGOP机构作为UTHSCSA的研究基地。 此申请寻求成员机构临床试验的支持 能够从广泛的患者样本中获得主要患者收益的组织 西南肿瘤学研究组临床试验候选人， 提交高质量的数据，并继续参与其 在美国从事重大科学和行政活动的调查人员 组。

Description (Adapted from the applicant's abstract): The Southwest Oncology Group Cancer Research Program of the University of Texas Health Science Center at San Antonio is a member institution multidisciplinary program dedicated to accrual of high numbers of patients to the studies of the Southwest Oncology Group and to high quality data collection from the member institution and its Cooperative Group Outreach Program (CGOP) Affiliates. The Principal Investigator and 48 collaborating investigators from Medical Oncology, Hematology, Surgical Oncology, Radiation Oncology, and Pathology maintain 20 uninterrupted years of participation in this cooperative clinical trials program. This program has achieved first or second rank among all participating member institutions in patient accrual for the past two years. 1,202 patients have been enrolled to Group studies by the member institution and its CGOPs from l/l/92 to 12/31/96 (363 patients by the member institution alone). Of these patients, 642 or 53 percent were women (217 or 60 percent of the member institution accrual), 185 or 15 percent were Hispanic (126 or 35 percent of the member institution accrual), and 152 or 13 percent were African-American (35 or 10 percent of the member institution accrual). The program has recruited 7 new CGOP affiliates for a total of 17 CGOP institutions for which UTHSCSA serves as research base. This application seeks support of a member institution clinical trials organization capable of major patient accrual from a broad sample of patient candidates to the clinical trials of the Southwest Oncology Group, submission of high quality data, and continued involvement of its investigators in major scientific and administrative activities in the Group.